223 VERSICAN IS A PROMISING CANDIDATE BIOMARKER IN THE COMBINATION OF DOCETAXEL WITH THALIDOMIDE AS SECOND LINE CHEMOTHERAPY IN CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL RESISTANCE

✍ Scribed by Shiina, Hiroaki; Yasumoto, Hiroaki; Hiraki, Miho; Arichi, Naoko; Mitsui, Yozo; Hiraoka, Takeo; Sumura, Masahiro; Honda, Satoshi; Igawa, Mikio

• Book ID: 118485003
• Publisher: Lippincott Williams and Wilkins
• Year: 2012
• Tongue: English
• Weight: 62 KB
• Volume: 187
• Category: Article
• ISSN: 0022-5347
• DOI: 10.1016/j.juro.2012.02.277